You are here:Home-Chemical Inhibitors & Agonists-PI3K/Akt/mTOR Pathway-PI3K-Alpelisib
Alpelisib

Chemical Structure : Alpelisib

CAS No.: 1217486-61-7

Alpelisib (BYL-719, NVP-BYL719)

Catalog No.: PC-20590Not For Human Use, Lab Use Only.

Alpelisib (NVP-BYL719, BYL719) is ia potent, selective, and orally active PI3Kα inhibitor with IC50 of 5 nM, >50-fold selectivity over p110γ/p110δ/p110β.

Packing Price Stock Quantity
25 mg $258 In stock
100 mg $698 In stock
200 mg Get quote
1 g Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

Alpelisib (NVP-BYL719, BYL719) is ia potent, selective, and orally active PI3Kα inhibitor with IC50 of 5 nM, >50-fold selectivity over p110γ/p110δ/p110β.
Alpelisib (BYL719) potently inhibits PIK3CA somatic mutations (H1047R, E545K) with IC50 of 4 nM.
Alpelisib (BYL719) potently inhibits Akt phosphorylation in cells transformed with PI3Kα (IC50=74 nM) and shows significant reduced inhibitory activity in PI3Kβ or PI3Kδ isoforms transformed cells (>15-fold).
Alpelisib (BYL719) (0-50 uM) inhibits the cell growth of osteosarcoma cell lines MG63, HOS, POS-1 and MOS-J in a dose-dependent manner.
Alpelisib (BYL719) potently suppresses proliferation and PI3K signaling in human breast cancer cells harboring PIK3CA(H1047R) in combination with lapatinib.
Alpelisib (BYL719) inhibits growth factor-independent KRASG12D BM colony formation and sensitizes cells to a low dose of the MEK inhibitor MEK162.

Physicochemical Properties

M.Wt 441.47
Formula C19H22F3N5O2S
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

(S)-N1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide

References

1. Furet P, et al. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3741-8.

2. Gobin B, et al. Int J Cancer. 2015 Feb 15;136(4):784-96.

3. Fritsch C, et al. Mol Cancer Ther. 2014 May;13(5):1117-29.

4. Elkabets M, et al. Sci Transl Med. 2013 Jul 31;5(196):196ra99.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: